Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LD PepGNP-Dengue
- Development stage
- Phase 1
- Lead developer
- Gylden Pharma
- Modality
- Vaccines & Immunotherapeutics, Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intradermal
01
Overview
LD PepGNP-Dengue is a low-dose, gold nanoparticle (GNP)-based, multi-valent synthetic peptide vaccine candidate. Developed by Gylden Pharma Ltd. with support from Emergex Vaccines Holding Limited, it is designed to prime CD8+ T-cell responses against all four serotypes of the dengue virus (DENV). The vaccine utilizes a T-cell priming cocktail of DENV ligandome peptides (2.5 nmol in the low-dose formulation) mounted on gold nanoparticles (14.8 μg gold content). Unlike traditional vaccines that focus on neutralizing antibodies, LD PepGNP-Dengue is engineered to confer protective immunity via cytotoxic T cells without inducing anti-DENV antibodies, thereby minimizing the risk of antibody-dependent enhancement (ADE) and severe dengue. It has been evaluated in a Phase 1 clinical trial (NCT04935801; 'naNO-DENGUE') in healthy adults, where it demonstrated a favorable safety profile and significant increases in dengue-specific CD8+ T-cell memory subsets.
- Other names
- naNO-DENGUE vaccineEmergex Dengue vaccine
02
Targets
HLA-B7CD8A (CD8 alpha/beta Coreceptor)
Beyond the preview
Go deeper on LD PepGNP-Dengue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LD PepGNP-Dengue.